Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $27.7 million.

  • Oncology Institute's Cash & Equivalents fell 4165.23% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 4165.23%. This contributed to the annual value of $49.7 million for FY2024, which is 4831.88% up from last year.
  • As of Q3 2025, Oncology Institute's Cash & Equivalents stood at $27.7 million, which was down 4165.23% from $30.3 million recorded in Q2 2025.
  • Oncology Institute's 5-year Cash & Equivalents high stood at $115.2 million for Q4 2021, and its period low was $11.5 million during Q3 2021.
  • Its 5-year average for Cash & Equivalents is $40.9 million, with a median of $33.5 million in 2023.
  • Per our database at Business Quant, Oncology Institute's Cash & Equivalents skyrocketed by 182020.67% in 2021 and then crashed by 8783.58% in 2022.
  • Over the past 5 years, Oncology Institute's Cash & Equivalents (Quarter) stood at $115.2 million in 2021, then plummeted by 87.84% to $14.0 million in 2022, then surged by 139.03% to $33.5 million in 2023, then surged by 48.32% to $49.7 million in 2024, then plummeted by 44.32% to $27.7 million in 2025.
  • Its Cash & Equivalents was $27.7 million in Q3 2025, compared to $30.3 million in Q2 2025 and $39.7 million in Q1 2025.